Visual cortex

NEC C&C Foundation Awards 2021 C&C Prize

Tuesday, October 12, 2021 - 7:56am

Because Dr. Kunihiko Fukushima's achievements were far-sighted and of great magnitude, we believe he is a worthy recipient of the C&C Prize.

Key Points: 
  • Because Dr. Kunihiko Fukushima's achievements were far-sighted and of great magnitude, we believe he is a worthy recipient of the C&C Prize.
  • His tireless commitment to making the dream of autonomously functioning robots into a reality makes him a worthy recipient of the C&C Prize.
  • Each prize winner receives a certificate, a plaque, and a cash award (ten million yen per group).
  • For additional information, please visit The NEC C&C Foundation website at: https://www.candc.or.jp/en/index.html
    NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world."

Contrary to Expectations, Study Finds Primate Neurons Have Fewer Synapses Than Mice in Visual Cortex

Tuesday, September 14, 2021 - 8:54pm

In a study comparing the brains of macaques and mice at the synaptic level, the researchers found that the primates had far fewer synapses per neuron compared to the rodents, in both excitatory and inhibitory neurons in layer 2/3 of the primary visual cortex.

Key Points: 
  • In a study comparing the brains of macaques and mice at the synaptic level, the researchers found that the primates had far fewer synapses per neuron compared to the rodents, in both excitatory and inhibitory neurons in layer 2/3 of the primary visual cortex.
  • They chose to examine both excitatory and inhibitory synapses, as most previous research had focused on only excitatory synapses.
  • Focusing on layer 2/3 neurons in the adult primary visual cortex made it easier to compare across species, as these neurons have distinct morphologies that are similar in both primates and mice.
  • Upon comparing the datasets, they found that primate neurons receive two to five times fewer excitatory and inhibitory synaptic connections than similar mouse neurons.

Luminopia One, a Digital Therapeutic for Amblyopia, Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial

Tuesday, September 14, 2021 - 1:00pm

The published study was a Phase 3 multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of Luminopia One to treat amblyopia in children aged 4-7.

Key Points: 
  • The published study was a Phase 3 multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of Luminopia One to treat amblyopia in children aged 4-7.
  • A link to the publication, Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia, can be found here: https://www.aaojournal.org/article/S0161-6420(21)00682-5/fulltext .
  • Luminopia One has been validated in multiple clinical trials, including a Phase 3 pivotal trial that demonstrated its safety and efficacy in children aged 4-7 for the treatment of amblyopia.
  • Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients.

NextMind brings Brain-Computer Interface wearable to IAA Mobility

Thursday, September 9, 2021 - 2:38pm

NextMind , a fast-growing neurotechnology startup, announced today that its award-winning brain-computer interface is empowering real-time control in a concept vehicle presented this week in Munich at IAA Mobility Sept. 7-12.

Key Points: 
  • NextMind , a fast-growing neurotechnology startup, announced today that its award-winning brain-computer interface is empowering real-time control in a concept vehicle presented this week in Munich at IAA Mobility Sept. 7-12.
  • While visitors to IAA Mobility can try out NextMind real-time controls for themselves, it will take more time before these technologies become widely integrated across consumer products.
  • A fast-growing tech startup, NextMind has developed a first-of-its-kind, brain-sensing wearable that delivers real-time device control using just a person's thoughts.
  • The remarkable NextMind brain-computer interface wearable was featured by ABC News , CNBC , VentureBeat , WIRED , etc.

Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study

Wednesday, August 11, 2021 - 11:00am

The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study.

Key Points: 
  • The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study.
  • The grant supplement is related to the $6.4 million NIH grant for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442.
  • Second Sight reported promising two-year data from the Orion trial on May 12, 2021.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

AEye Introduces Next Generation of Artificial Perception: New Dynamic Vixels™ Enhancement to iDAR™ Better Mimics the Human Visual Cortex

Tuesday, May 22, 2018 - 1:00pm

"There is an ongoing argument about whether camera-based vision systems or LiDAR-based sensor systems are better," said Luis Dussan, Founder and CEO of AEye.

Key Points: 
  • "There is an ongoing argument about whether camera-based vision systems or LiDAR-based sensor systems are better," said Luis Dussan, Founder and CEO of AEye.
  • "Our answer is that both are required they complement each other and provide a more complete sensor array for artificial perception systems.
  • AEye's iDAR perception system mimics how a human's visual cortex evaluates a scene and calculates potential driving hazards.
  • AEye is an artificial perception pioneer and creator of iDAR, a new form of intelligent data collection that acts as the eyes and visual cortex of autonomous vehicles.